Literature DB >> 19610116

Experience with hemihyperplasia and Beckwith-Wiedemann syndrome surveillance protocol.

Yuri A Zarate1, Rafael Mena, Lisa J Martin, Paul Steele, Bradley T Tinkle, Robert J Hopkin.   

Abstract

Beckwith-Wiedemann syndrome (BWS) and isolated hemihyperplasia (IHH) are two well known overgrowth conditions that are associated with cancer predisposition. Multiple surveillance protocols have been proposed to detect the most commonly reported tumor types Wilms tumor and hepatoblastoma. We reviewed the history of our patients who were part of this monitoring protocol. Information from 63 cases was collected retrospectively while another 63 control samples for AFP measurement were obtained prospectively. Twenty-five (40%) patients had an ultrasound abnormality, the most frequent being nephromegaly/size discrepancy. Two patients had well documented cases of tumors/tumor precursor (2/63:3.2%) detected by ultrasound images. Three hundred thirty-six separate AFP values were available with values above 50,000 ng/ml seen in three patients older than 2 months, one with hepatoblastoma and two other with hemangiomas/hemangioendotheliomas. There was no clear difference in the range of AFP values between previously reported controls, our own normal population and affected patients. In conclusion, ultrasound surveillance detected renal and liver pathology including benign and malignant lesions. The known variability of AFP in normal neonates and patients with BWS makes interpretation difficult in early infancy. Very high AFP values did seem to be correlated with risk for identifiable liver lesions. Determination of the natural changes in AFP levels over time will allow more appropriate comparison. 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19610116     DOI: 10.1002/ajmg.a.32966

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  14 in total

1.  Development of the Serum α-Fetoprotein Reference Range in Patients with Beckwith-Wiedemann Spectrum.

Authors:  Kelly A Duffy; Jennifer L Cohen; Okan U Elci; Jennifer M Kalish
Journal:  J Pediatr       Date:  2019-06-22       Impact factor: 4.406

2.  Tumor Screening in Beckwith-Wiedemann Syndrome: Parental Perspectives.

Authors:  Kelly A Duffy; Katheryn L Grand; Kristin Zelley; Jennifer M Kalish
Journal:  J Genet Couns       Date:  2017-12-04       Impact factor: 2.537

3.  (Epi)genotype-phenotype correlations in Beckwith-Wiedemann syndrome.

Authors:  Alessandro Mussa; Silvia Russo; Agostina De Crescenzo; Andrea Freschi; Luciano Calzari; Silvia Maitz; Marina Macchiaiolo; Cristina Molinatto; Giuseppina Baldassarre; Milena Mariani; Luigi Tarani; Maria Francesca Bedeschi; Donatella Milani; Daniela Melis; Andrea Bartuli; Maria Vittoria Cubellis; Angelo Selicorni; Margherita Cirillo Silengo; Lidia Larizza; Andrea Riccio; Giovanni Battista Ferrero
Journal:  Eur J Hum Genet       Date:  2015-04-22       Impact factor: 4.246

4.  The utility of alpha-fetoprotein screening in Beckwith-Wiedemann syndrome.

Authors:  Kelly A Duffy; Matthew A Deardorff; Jennifer M Kalish
Journal:  Am J Med Genet A       Date:  2017-02-04       Impact factor: 2.802

Review 5.  Educational paper: screening in cancer predisposition syndromes: guidelines for the general pediatrician.

Authors:  Alexis Teplick; Megan Kowalski; Jaclyn A Biegel; Kim E Nichols
Journal:  Eur J Pediatr       Date:  2011-01-06       Impact factor: 3.183

6.  Characterization of the Beckwith-Wiedemann spectrum: Diagnosis and management.

Authors:  Kelly A Duffy; Christopher M Cielo; Jennifer L Cohen; Christina X Gonzalez-Gandolfi; Jessica R Griff; Evan R Hathaway; Jonida Kupa; Jesse A Taylor; Kathleen H Wang; Arupa Ganguly; Matthew A Deardorff; Jennifer M Kalish
Journal:  Am J Med Genet C Semin Med Genet       Date:  2019-08-30       Impact factor: 3.908

7.  Defining an optimal time window to screen for hepatoblastoma in children with Beckwith-Wiedemann syndrome.

Authors:  Alessandro Mussa; Kelly A Duffy; Diana Carli; Giovanni Battista Ferrero; Jennifer M Kalish
Journal:  Pediatr Blood Cancer       Date:  2018-09-30       Impact factor: 3.167

Review 8.  Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma.

Authors:  Jennifer M Kalish; Leslie Doros; Lee J Helman; Raoul C Hennekam; Roland P Kuiper; Saskia M Maas; Eamonn R Maher; Kim E Nichols; Sharon E Plon; Christopher C Porter; Surya Rednam; Kris Ann P Schultz; Lisa J States; Gail E Tomlinson; Kristin Zelley; Todd E Druley
Journal:  Clin Cancer Res       Date:  2017-07-01       Impact factor: 12.531

9.  Tumor screening in Beckwith-Wiedemann syndrome-To screen or not to screen?

Authors:  Jennifer M Kalish; Matthew A Deardorff
Journal:  Am J Med Genet A       Date:  2016-09       Impact factor: 2.802

Review 10.  Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome: an international consensus statement.

Authors:  Frédéric Brioude; Jennifer M Kalish; Alessandro Mussa; Alison C Foster; Jet Bliek; Giovanni Battista Ferrero; Susanne E Boonen; Trevor Cole; Robert Baker; Monica Bertoletti; Guido Cocchi; Carole Coze; Maurizio De Pellegrin; Khalid Hussain; Abdulla Ibrahim; Mark D Kilby; Malgorzata Krajewska-Walasek; Christian P Kratz; Edmund J Ladusans; Pablo Lapunzina; Yves Le Bouc; Saskia M Maas; Fiona Macdonald; Katrin Õunap; Licia Peruzzi; Sylvie Rossignol; Silvia Russo; Caroleen Shipster; Agata Skórka; Katrina Tatton-Brown; Jair Tenorio; Chiara Tortora; Karen Grønskov; Irène Netchine; Raoul C Hennekam; Dirk Prawitt; Zeynep Tümer; Thomas Eggermann; Deborah J G Mackay; Andrea Riccio; Eamonn R Maher
Journal:  Nat Rev Endocrinol       Date:  2018-01-29       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.